Peter Winkley is a seasoned C-Suite executive with over 30 years of experience in financial reporting, governance, treasury, taxation, risk management, and M&A for large public companies. He is currently the Vice President of Finance and CFO at Algoma Central Corporation, where he leads a team of 30 staff and is responsible for financial discipline, strategy implementation, and a $400M refinancing. Previously he held senior finance roles at Therapure Biopharmaceutical and MDS Inc, where he established financial processes and led multi-million dollar acquisitions and insurance programs. He has extensive public company experience across industries in Canada and internationally.

1. PETER WINKLEY, C.P.A, C.A.
PROFILE
A seasoned C-Suite Executive with significant public company experience, demonstrating the
following competencies:
 Extensive financial reporting and financial governance knowledge, supplemented by solid
treasury, taxation, and risk management experience with Canadian based large cap public
companies with global operations.
 Seasoned M&A professional with substantial experience in deal structure, financing, due
diligence, and deal execution for both purchases and sales of businesses.
 Experienced in all types of capital and fund raising, including bank revolvers and term
facilities, private placement notes, convertible debentures, and equity.
 Disciplined and results driven, with extensive knowledge and experience in financial
management, strategy development, and business risk management.
 Strong communication and presentation skills; responsible for award-winning financial
reports and maintenance of relationships with capital markets.
 Demonstrated financial leadership in environments with tight deadlines and demanding
operating parameters.
CAREER EXPERIENCE
ALGOMACENTRAL CORPORATION 2010 – Present
Algoma Central Corporation owns and operates the largest fleet of Canadian flagged dry-bulk
freighters and product tankers operating on the Great Lakes and St. Lawrence Waterway and
has growing international operations.
Vice-President, Finance and Chief Financial Officer
Reporting to the Chief Executive Officer, I lead a staff of over 30 staff in finance and IT. I am
responsible for maintaining financial discipline and internal controls, corporate treasury, taxation
and global insurance, compliance with public company regulatory requirements, and investor
relations and corporate communications. In addition, as a member of Algoma’s small executive
team, I am responsible for implementation of corporate strategy. Key achievements include:
 Completed a $400 million refinancing of the Company, including the Company’s first use of
the US Private Placement market and its first convertible debenture issue.
 As part of the executive management team, played a leading role in the $85 million
acquisition of the non-controlling interest in the Company’s key domestic dry-bulk business.
 Following the acquisition, led the integration of finance and IT functions of the Company and
the acquired business, including a 10% downsizing to realize planned acquisition synergies.
Associated roles include: Chair, Canadian Shipowners Mutual Assurance Association; Director
and Audit Committee Chair, The Standard Compensation Act Liability Association Limited; and,
Board Member, The North of England P&I Association Limited.

2. PETER WINKLEY, C.P.A., C.A. Page 2
THERAPURE BIOPHARMAINC. 2008 – 2009
Therapure is a biopharmaceutical contract manufacturing company established in 2008.
Vice-President, Finance and Chief Financial Officer
Reporting to the Chief Executive Officer as part of the founding executive management team of
Therapure, I led a staff of 6 in finance, legal services, IT and HR. I was responsible for
establishing initial processes and controls as the company formulated and implemented a
strategic plan designed to convert a single-product manufacturing plant into a flexible, multiple-
service capable contract development and manufacturing facility.
MDS INC. 1995 – 2008
MDS was a public company in the global life sciences industry that provided market-leading
products and services to customers for the development of drugs and the diagnosis of disease.
Various roles to Vice-President, Corporate Finance and Treasurer
Reporting to the Chief Financial Officer, I led a core staff of 5 on the Corporate Finance team as
MDS grew from less than $1 billion in revenues to nearly $1.9 billion and from locations in 3
countries to locations in 25 countries. I was responsible for all financial publications and filings
of the company, including annual reports that won numerous disclosure awards in Canada and
the US. In my various roles with MDS, I developed and implemented reporting processes for
MDS’s global operations and led the initial stages of conversion of the Company from an
operational reporting structure to a functional reporting structure for global finance, successfully
integrating a global staff of 160 finance professionals.
During my career at MDS, I created and led a centralized Corporate Treasury with responsibility
for banking, financing, and derivative and hedging transactions. During this period I
implemented a coordinated, company-wide currency hedging program that produced over $200
million of currency gains over five years. Corporate Treasury also managed and integrated a
$15 million global insurance program, and I conceived and implemented a captive insurance
program that resulted in $3.5 million of annual insurance savings for seven years.
While at MDS, I was a key member of and ultimately led the finance team responsible for the
deal structure, financing, and financial due diligence related to the strategic acquisitions of
several smaller drug development companies leading up to the acquisition of a Canadian public
company in the sector in March, 2000.
ERNST & YOUNG 1982 – 1995
Staff Accountant to Senior Manager
EDUCATION
Chartered Accountant, Ontario (1984)
Bachelor of Commerce - University of Toronto (1982)
OTHER
Director and Chair of Audit Committee and later Chairman, SQI Diagnostics Inc. (2007 to 2015)